MedPlus Health Services Limited has announced significant board-level changes. The company has appointed Mr. Ajit Pandurang Rangnekar and Mr. Mohankrishna Reddy Arvabumi as Non-Executive Independent Directors, effective May 20, 2026, for a five-year term. Additionally, the Board has approved the reappointment of Mr. Gangadi Madhukar Reddy as the Managing Director of the Company for another five-year term, commencing August 03, 2026, subject to approval from the company’s members.
Board Strengthened with New Independent Directors
As part of its commitment to robust corporate governance and strategic oversight, MedPlus has inducted two distinguished professionals to its Board of Directors. Mr. Ajit Pandurang Rangnekar brings over 50 years of extensive experience in leadership, consulting, and finance. Similarly, Mr. Mohankrishna Reddy Arvabumi joins the Board with over three decades of expertise in finance and strategy, having previously held senior leadership positions at major financial and technological institutions.
Strategic Leadership Continuity
The company also confirmed the reappointment of Mr. Gangadi Madhukar Reddy as the Managing Director. A promoter of MedPlus, Mr. Reddy has been instrumental in scaling the company into a leading pharmacy retail and healthcare provider. His new term will officially commence on August 03, 2026, and extend for a period of five years. This leadership continuity is expected to further drive the organization’s focus on operational excellence, technological integration, and long-term value creation.
Leadership Profiles
The newly appointed Independent Directors bring diverse perspectives to the company. Mr. Rangnekar, an IIT Bombay and IIM Ahmedabad alumnus, has deep expertise in corporate strategy and supply chain optimization. Mr. Mohankrishna Reddy holds a Master’s degree in Finance and has a strong background in investment banking and mergers and acquisitions. These appointments are designed to bolster the company’s strategic roadmap in the evolving healthcare landscape.
Source: BSE
